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Available online 29 April 2014Abstract The idea that the body's own stem cells could act as a repair kit for many conditions, including cardiac repair, underpins
regenerative medicine. While progress is being made, with hundreds of clinical trials underway to evaluate possible autologous
cell-based therapies, some patients and physicians are not prepared to wait and are pursuing treatments without evidence that the
proposed treatments are effective, or even safe. This article explores the inherent tension between patients, practitioners and the
need to regulate the development and commercialization of new cellular therapies — even when the cells come from the patient.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 647
Rise of autologous ‘stem cell’ therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 648
Curbing provision of unproven stem cell treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 649
Expected standards in medical practice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 649
Community demand and expectation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 650
Looking forward . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 651
Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 652
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 652
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 652
1⁎ Corresponding author at: Level 2, Melbourne Brain Centre, 30 Royal
Parade, The University of Melbourne, Parkville, Victoria 3010, Australia.
E-mail address: megan.munsie@unimelb.edu.au (M. Munsie).
http://dx.doi.org/10.1016/j.scr.2014.04.014
1873-5061/© 2014 The Authors. Published by Elsevier B.V. This
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The possibility that stem cells could act as a repair kit to
restore function following disease or injury has long been
heralded as the next revolution in medicine. Although there
remain few established stem cell-based treatments beyondis an open access article under the CC BY-NC-ND license
648 M. Munsie, I. Hyunthe use of hematopoietic stem cell (HSC) transplants for
leukemia and certain other diseases of the blood and immune
system (Daley, 2012), extensive media coverage has fuelled
community expectation as it depicts stem cell research much
closer to clinical application than in reality it is. For example,
while most clinical trials over the last decade were early
phase studies using stem cells for cancer and graft-versus-host
disease, the majority of newspaper articles during the
same period focused on the potential use of stem cells for
neurological conditions, cardiovascular disease and diabetes
(Bubela et al, 2012). Heightened community expectation is
also reflected in survey data where perceptions of the benefits
of stem cell research are far greater than perceptions of risk
(DIISR, 2010; Downey and Geransar, 2008).
For many who look to stem cells as a means to alleviate their
suffering, or that of their loved one, such high expectations are
unlikely to be met in the near future. Although the number of
clinical trials for novel applications of stem cells has risen
rapidly since 2004 (Li et al, 2013), the majority of the trials are
focused on establishing safety with enrollment duly limited.
Frustrated by the lack of access to clinical trials, many have
turned to those offering stem cell treatment outside clinical
trials (Kiatpongsan and Sipp, 2009; Lau et al, 2008; Petersen et
al, 2013).
In the information age, finding a ‘stem cell’ therapy is
not difficult. A simple on-line search will reveal numerous
websites that rely extensively on compelling patient testi-
monials to promote their treatment and leave the viewer
with the impression that a cure is “but a simple injection
away” (Ogbogu et al, 2013; Petersen and Seear, 2011). Some
providers offer to use the patient's own stem cells – so called
autologous treatments – while others claim to use donated
sources of stem cells including fetal tissue, cord blood and
human embryos. However, what is exactly being delivered
to the patient – and indeed if it even contains stem cells –
is often difficult to ascertain as few providers have in-
dependent verification of the products they administer.
The mode of delivery of the cells also varies, with some
providers using intramuscular or intravenous injections,
while others use intrathecal or intracranial delivery of the
cells (Lau et al, 2008; Petersen et al, 2013). Claiming to be
able to treat conditions as diverse as spinal cord injury,
heart disease, cerebral palsy, multiple sclerosis, asthma,
arthritis and chronic fatigue syndrome, the websites offer
little in the way of scientific evidence to justify these
“optimistic portrayals of stem cell treatments”(Petersen
and Seear, 2011).
Although not as frequently promoted as orthopedic and
neurological applications, ‘stem cell’ treatments to improve
cardiac function are offered. For example, an Australian
patient sought treatment in Thailand for his heart disease
and diabetes using ex vivo expanded bone-marrow cells
stating that there was a marked improvement in his heart's
ejection fraction—“rising from below 20% to over 50%”
following the treatment (Stem Cell China News, 2009). Such
treatments are expensive with many relying on community
fundraising to enable their treatment (Petersen et al, 2013),
as can be seen from the following extract taken from a wife's
plea for help for her husband:
“Our family and friends have done a lot of research… stem
cells are harvested from his blood and then put back into hisheart…. After speaking to several couples that have gone
through exactly the same as us, our belief is that this is the
better road…. Although this is what we so desperately want,
we have exhausted all of our funds.”
[GoFundMe (2012)]
While concern about patients traveling abroad to seek
out stem cell treatments not available at home has been
well documented, with the term ‘stem cell tourism’ used
to describe this phenomenon (Kiatpongsan and Sipp, 2009;
Master and Resnik, 2011; Ryan et al, 2010), it is what is
happening in our ‘own backyard’ in relation to autologous
treatments that requires closer examination and is the
focus of this paper.Rise of autologous ‘stem cell’ therapies
The idea that you can use your own stem cells is highly
appealing for many patients. Simple messages – such as the
cells won't be rejected; that the risk of a disease is avoided,
and that using your own cells is more ‘ethical’ – resonate in
the community and are reinforced in direct-to-consumer
marketing strategies employed by providers. Indeed those
opposing the use of human embryos in research have long
promoted adult stem cell treatments as a more ethically
acceptable alternative, despite criticisms that such por-
trayals fail to acknowledge that the cited treatments await
clinical validation (Smith et al, 2006) — a warning that can
still be leveled at many promoting autologous cell treat-
ments today.
To a large extent the growth in unproven autologous stem
cell treatments has been enabled by the use of liposuction
techniques. Despite calls by the American Society of Plastic
Surgeons and the American Society of Aesthetic Plastic Surgery
warning that ‘stem cell’ face-lifts and breast augmentation are
“not adequately supported by clinical evidence” (Eaves et al,
2012), cosmetic surgeons have started to offer these services to
their clientele. In Australia, cosmetic surgeons and others are
goingwell beyond localized administration of cells derived from
liposuction for esthetic surgery. For less than $10,000 Australian
patients are being offered intra-articular injections of adipose-
derived cell extracts for osteoarthritis and cartilage repair, as
well as intravenous delivery of crude cellular extract for stroke,
multiple sclerosis, retinal neuropathy, spinal cord injury,
Amyotrophic Lateral Sclerosis and even autism. All of these
treatments are being offered as a medical procedure outside
clinical trials.
The underlying justification for such adipose-derived
procedures is the assumption that the cellular extract
contains mesenchymal stem cells (MSCs) — a type of stromal
cell isolated from a wide variety of sources including bone
marrow, fat, dental pulp and placental tissue and one of the
most common sources of stem cells in new clinical trials over
the last decade (Li et al, 2013). For the providers they are an
attractive source as they are relatively easy to isolate from
the patient, are reputed to be able to form cartilage, bone
and muscle, and also exert immunomodulatory properties
enabling them to act as an “injury drugstore” (Caplan and
Correa, 2011). However, what are exactly MSCs and their use
in regenerative medicine – and even whether they should be
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the scientific community (Bianco et al, 2013a; Shen, 2013).
Interestingly, autologous cell therapies are often pro-
moted as being ‘natural’ and having ‘no risk’ because they
come from ‘you’. However, safety should not be assumed in
all circumstances. The recent report of bone fragments
growing around a patient's eye following a stem cell facelift
(Jabr, 2012), as well as the lesions that developed in the
kidney of a woman who received marrow-derived cells
(Thirabanjasak et al, 2010), highlights the potential hazards
of early adoption of unproven stem cell treatments — even
when the cells come from the patient.
Curbing provision of unproven stem
cell treatments
In recognition of the growth of commercial practices marketing
unproven stem cell treatments, the International Society for
Stem Cell Research (ISSCR) in 2007 established a task force of
scientific, medical, and bioethical experts to develop a
comprehensive set of performance guidelines for the clinical
translation of stem cell research. These guidelines address any
attempt to develop novel clinical applications of stem cells and
their direct derivatives, including the use of HSCs and other
somatic stem cells outside their established standards of care,
specifically voicing concern about the “potential physical,
psychological, and financial harm to patients who pursue
unproven stem cell-based therapies and the general lack of
scientific transparency and professional accountability of those
engaged in these activities” (Hyun et al., 2008; ISSCR, 2008).
In particular these guidelines included a series of recom-
mendations for the responsible administration of unproven
stem cell interventions outside a clinical trial context. The
ISSCR guidelines allow some room formedical innovation during
the course of patient care through the provision of
unproven stem cell interventions, but only under very
special circumstances (Lindvall and Hyun, 2009). These
exceptional circumstances involve just small numbers
of seriously ill patients who would be cared for under a
stringent set of oversight requirements including independent
peer review of the proposed innovative stem cell procedure and
its scientific rationale, institutional accountability, rigorous
informed consent and careful patient monitoring, transparen-
cy, speedy adverse-event reporting, and a committed plan by
clinician-scientists to move toward a formal clinical trial after
experience with the intervention in a few patients (Hyun et al.,
2008).
For all other circumstances that do not meet the criteria
governing responsible stem cell-based innovative care, the
ISSCR included an additional clear statement within the
guidelines entitled ‘Position on Unproven Commercial Stem
Cell Interventions.’ This position statement articulates in no
uncertain terms that “the ISSCR condemns the administration
of unproven uses of stem cells or their direct derivatives to a
large series of patients outside of a clinical trial, particularly
when patients are charged for such services. Scientists and
clinicians should not participate in such activities as a matter
of professional ethics.” (ISSCR, 2008, p. 5).
In 2013, following a rise in the number of providers of
autologous-based stem cell treatments, the ISSCR released an
additional statement reiterating the criteria under which stemcell research should be translated – even when the cells are
from the patient – and calling on medical licensing bodies,
legal authorities, patient advocacy organizations, physicians,
and others to exercise their influence to discourage commer-
cial provision of unproven autologous cell-based interventions
outside of clinical trials (ISSCR, 2013).
However, regulating this area is proving to be extremely
challenging with autologous-based cell therapies often able
to be couched as ‘medical practice’ and therefore able to
avoid the exacting standards imposed by regulators regarding
manufacturing and evaluation standards (DeFrancesco, 2012;
Sipp, 2013). A recent ruling from the US Court of Appeals for
the District of Columbia Circuit provides some guidance. In this
case the appellants were unable to convince the Court that
the administration of ex vivo expanded autologous MSCs –
derived from bone marrow or synovial fluid –was a medical
procedure and upheld the right of the Food and Drug
Administration (FDA) to regulate the manufacture of this
product (United States v. Regenerative Sciences and LLC,
2014). However, FDA's rights to regulate all autologous cell
therapies – especially where there is less extensive ex vivo
manipulation – remain to be tested.
In other jurisdictions such as Australia there are no such
caveats with respect to the degree of manipulation. Under
regulations introduced in 2011, autologous cell therapies
provided by registered Australian doctors do not have to
comply with stringent requirements set by local regulators
of medicines and devices — the Therapeutic Goods
Administration (Trickett and Wall, 2011). Rather such
practices are seen as medical practices where oversight
falls within the remit of the Australian Health Practitioner
Regulatory Agency. Although simple modifications to the
Australian regulations – such as incorporating recognition of
the inherent risks in extending the use of cells beyondwhat they
usually do in the body (i.e. non-homologous use) andmaking it a
requirement that cells are prepared in accredited laboratories
– could enhance the oversight and curb unproven practices,
many Australian scientists and clinicians fear that such changes
will not occur until there are serious adverse outcomes.Expected standards in medical practice
Attempts by clinicians to frame autologous stem cell
treatments under the aegis of medical practice do not
shield these treatments from further ethical scrutiny.
While it is true that physicians normally enjoy a consider-
able degree of freedom in deciding how to best treat their
patients, it is also true that there exists a series of medical
professional norms that constrain the range of this
discretionary therapeutic privilege. It is worth highlight-
ing that the ISSCR's position statement on unproven
commercial stem cell therapies makes a direct appeal to
the notion of professional ethics, and in this way brings
medical professionalism into the discussion.
Even if one assumes for the sake of argument that the FDA
and other relevantly similar regulatory agencies do not have
jurisdiction over the administration of autologous stem cell
therapies, physicians are still constrained by the standards of
medical professional ethics. In fact, medical professionalism
calls on doctors to abide by a code of conduct that is
650 M. Munsie, I. Hyuninconsistent with the offer to sell patients unproven autologous
commercial stem cell therapies.
Perhaps the most well-known recent articulation of such a
set of medical professional standards is provided in the
Physician Charter, which was drafted by the American Board
of Internal Medicine (ABIM) Foundation, the American College
of Physicians Foundation, and the European Federation of
Internal Medicine (ABIM Foundation, 2002). This document is
applicable to physicians worldwide, and it was published
simultaneously in The Annals of Internal Medicine and The
Lancet in 2002 (ABIM Foundation, 2002). The Physician Charter
reaffirms the aspirational ideal that physicians must place the
interests of their patients above their own personal interests,
including their own private financial motivations. Market
forces must not compromise the principle of the primacy of
patient welfare. The Physician Charter then goes on to
elucidate the many professional responsibilities of physicians,
three of which are especially relevant to the selling of
unproven stem cell therapies.
The first professional responsibility involves the medi-
cal profession's collective interest in ensuring that all of
its members are competent medical practitioners. This
commitment to competence calls on physicians to work
collaboratively with other professionals to reduce medical
error and increase patient safety. Related to this commit-
ment to competence is the physician's professional re-
sponsibility to support and foster scientific knowledge. As
the Charter states:
Much of medicine's contract with society is based on the
integrity and appropriate use of scientific knowledge and
technology. Physicians have a duty to uphold scientific
standards, to promote research, and to create new
knowledge and ensure its appropriate use. The profession
is responsible for the integrity of this knowledge, which is
based on scientific evidence and physician experience.
[ABIM Foundation (2002, p. 245)]
Finally, the Charter reminds us that professionalism
requires physicians to manage their financial conflicts of
interests carefully and rigorously, since failure to do so could
undermine the principle of primacy of patient welfare.
Together, these three professional responsibilities – a
commitment to medical competence, a commitment to
scientific knowledge and evidence, and the need to avoid
financial conflicts of interest – militate against the propo-
sition that proffering unproven commercial stem cell
therapies to patients is ethically unproblematic for physi-
cians. The norms of medical professionalism make it very
difficult to justify the view that physicians should be free
to offer whatever they want to patients without answering
to anyone else, let alone an outside group like the ISSCR. As
members of the medical profession, physicians are mini-
mally ethically required to engage in a process of
self-regulation whereby members of that profession are
obligated to accept internal evaluation and external
scrutiny of all major aspects of their professional perfor-
mance. Physicians are also obligated by these norms to
offer their patients only therapies that are scientifically
well-grounded and are open to independent critical review
by domain experts.Such views that place special moral obligations on health
professionals are prevalent, long-standing, and justifiable.
Physicians are granted the special privilege of tending to the
ill only because of an implicit contractual premise that the
proper social role of the physician is to use his or her special
knowledge for the general welfare of society. A physician is
not entitled to exploit his or her special knowledge for
personal gain alone, as business entrepreneurs may. The
moral duties of non-maleficence (first do no harm) and
beneficence (promote the welfare of others) are central to
understanding the medical profession as a social institution
that lies outside the commercial marketplace. According to
commercialism, the primary ethical obligations that matter
are that the seller does not coerce, cheat, or defraud others.
The principle of caveat emptor (buyer beware) governs all other
aspects of the seller–buyer relationship. The physician–patient
relationship, on the other hand, is a fiduciary bond whereby the
doctor has a moral duty to look after the best interests of the
patient. This fiduciary relationship, which characterizes all
physician–patient interactions, is derived from the power
differential that exists between the expert and the
non-expert and the non-expert's vulnerability caused by illness
and his or her necessary trust in the doctor (Brody, 1992).
Because power differentials and vulnerability are not
inherent components of the commercial relationship, it is
inappropriate to try to squeeze the physician–patient relation-
ship into the framework of commercial transactions and
consumers' marketplace freedom. The physician's professional
moral duties of patient beneficence and non-maleficence
require him or her to offer only medical treatments that are
supported by an evidence-based approach. These two moral
duties, combined with the medical professional's other com-
mitment to scientific knowledge and rigor, undermine the
position that physicians ought to be able to sell unproven stem
cell therapies to any patient who is willing to purchase them.
The rules of themarketplace ignore the special moral character
of the medical profession.Community demand and expectation
Unfortunately, autologous stem cell therapies continue to be
presented and viewed under a commercialistic social lens which
remains insensitive to the medical professional norms just
described. This makes it all too easy for clinicians to offer these
treatments as a matter of free consumer choice. For those
seeking to benefit from stem cell research, the promise of stem
cells understandably offers great ‘hope’ (Petersen et al, 2013),
with the ability to access possible therapies using your own cells
even more attractive. A recent study of Australians who have
pursued stem cell treatments abroad highlights that few look
beyond the financial costs (Petersen et al, 2013). Commenting
on her decision to take her child abroad for an autologous-based
stem cell treatment one participant stated:
It came down to the worst that could happen was nothing
really, the worst that could happen was we could spend
our money and… gotten no result.
[Petersen et al (2013)]
Not only are the potential risks to health rarely
acknowledged by patients – even when highly invasive
651A question of ethics: Selling autologous stem cell therapies flaunts professional standardstechniques are used to deliver the cells – but also there is a
degree of ownership about ‘my cells’. For example, in
reaction to steps taken by the FDA in relation to the
practices of a company in Texas which was expanding MSCs
taken from abdominal fat, clients and those looking to use
this service were outraged that the government was telling
them what they could do with their bodies (Aldhous, 2013)
and an online campaign was mounted to press congress to
protect American's right to “access our own stem cells”
(Patients for Stem Cells, 2013).
Perhaps the most graphic illustration of the tension
between patients, providers, scientists and regulators is
what has been happening in Italy. In response to moves by
the Italian government to restrict access to unproven
treatments, aggrieved protesters have blocked traffic and
stormed parliament to make their frustration known. For
many years the Stamina Foundation had been treating
patients, including many children, with unproven cell
therapies by reputedly using MSCs extracted and expanded
from the patient's own bone marrow or from allogeneic
sources (Bianco et al, 2013b). Following an inspection of
their facilities in 2012 Agenzia Italiana del Farmaco (AIFA) –
the Italian Medicines Agency – intervened to stop the
treatments due to concerns about how the cells were
prepared. There ensured a very public exchange in the
media between those calling for caution and the need for
regulation, and those demanding ‘compassionate use’ of this
therapy to be allowed for these sick and dying patients
(Abbott, 2013). In response to the public pressure, the
Senate passed permissive legislation to remove cell thera-
pies from the oversight of AIFA thereby enabling Stamina to
continue to offer treatment. This was subsequently modified
to limit treatment to current patients in a government
funded clinical trial provided that European Union regula-
tions were met including that cells were manufactured in
compliance with Good Manufacturing Practice and that an
expert panel was convened to oversee the trial design
(Margottini, 2013a). However a resolution on the rights or
otherwise of Stamina to provide treatment remains a long
way from being reached. A series of recent developments
has seen the expert panel state that there was “no scientific
foundation” to justify the trial and called for it to be
abandoned (Margottini, 2013b), only to be followed by
Stamina instigating successful legal action to have the
expert committee declared invalid (Abbott, 2014). While a
new committee is to be appointed, for those at the center of
this turbulent dispute – the patients and their families –
their frustration no doubt continues.
However not all patients are satisfied with what they
have paid for. Patients in Japan have recently commenced
legal action following unsatisfactory outcomes from autolo-
gous adipose-derived treatments (Sakagami and Yoneyama,
2013), others in the US have sued for failure to deliver on
anti-aging claims (Cyranoski, 2012) and in Italy, there is also
an ongoing fraud investigation into Stamina Foundation's
activities (Margottini, 2013b). While negative publicity and
punitive findings associated with these cases may restrict
the activities of individual providers, and dampen enthusi-
asm of others, this may not be enough to slow the
commercialization of autologous stem cell therapy. While
in many countries, most notably in the US, the market
regulation of goods and services can occur through thepersonal injury (torts) legal system, this post hoc means of
regulation is non-ideal because serious harms must first be
suffered by patients and their families. Preventive regula-
tion that reinforces medical professional ethical duties more
proactively should be the preferred route to managing
autologous stem cell therapies.
Looking forward
There has been considerable effort expended on increasing
awareness in the community about the risks of pursing
stem cell treatment outside clinical trials (ASCC, 2009;
ISSCR, 2010; Master and Caulfield, 2014; NSCFA, 2013). With
patients rarely acknowledging risk other than financial risk
associated with perusing treatment abroad using donated
sources (Petersen et al., 2013), the blatant promotion of
‘natural’ and ‘no risk’ autologous stem cell interventions
posses a new and concerning development. This is partic-
ularly so given that the framing of such treatment is heavily
influenced by an inherent conflict of interest. While providers
selling such interventions place them as part of legitimate
medical practice and others as a possible innovativemedicine,
the basic premise of assessment of risks against benefits by the
independent regulators should remain paramount. Although
some patients and providers may see this as interference
resulting in an unnecessary delay in potentially ‘life-saving’
treatment, as stated in a recent commentary highlighting
the dangers of doing translational medicine in reverse,
“extraordinary claims” should require “extraordinary
evidence” (Bianco, 2013).
Patient demand should not be met by providing unproven
treatments in a commercial context, especially at the
expense of important professional scientific and medical
norms. However, it needs to be recognized that this will not
be persuasive for many who see stem cells as their only
hope. Managing such unmet community expectation is going
to take “more than providing decision makers with the right
information” (Hyun, 2013). Health and medical profes-
sionals need to acknowledge and more proactively manage
the hope that patients and their families invest in stem cell
science (Hyun, 2013; Petersen et al, 2013). We need to
continue to encourage hope in medical research, including
stem cell research, but recognize that clinical translation of
basic research takes time. We need to address the
misconception that it is the regulators that are ‘costing
you your life’, and we need to remind clinicians and the
public of the social importance of medical professionalism
and the fiduciary nature of the doctor–patient relationship.
While steps to curb the sale of autologous-based cell
interventions through addressing regulatory ambiguity and
reinforcing existing standards of medical professional and
ethical conduct are welcomed and essential, this needs
to be done in a concert with managing community
expectations.
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